Gilead: Focus on remdesivir’s 2019-nCoV efficacy, permission talks too early
Gilead Sciences Inc said on Thursday that its focus is now on rapidly determining remdesivir's potential as a treatment for the 2019 novel coronavirus, rather than discussing compulsory licensing or…